SLS
vs
S&P 500
SLS
S&P 500
Over the past 12 months, SLS has significantly outperformed S&P 500, delivering a return of +198% compared to the S&P 500's +14% growth.
Stocks Performance
SLS vs S&P 500
Performance Gap
SLS vs S&P 500
Performance By Year
SLS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sellas Life Sciences Group Inc
Glance View
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 11 full-time employees. The company went IPO on 2008-03-12. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.
